http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H11139989-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bec96a436917f3e174b464cdca33dc3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 1997-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d8d9ff39368404a24b3bbb3d76760ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f8fd7c3574916f56a5a0c3bcd8c2958 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f3cae0566c1d9240774cc2112ebbe13 |
| publicationDate | 1999-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H11139989-A |
| titleOfInvention | Remedy for osteoporosis and osteopenia patients having selective gene |
| abstract | [PROBLEMS] To prevent multiple drug administration of a therapeutic drug by selectively administering a drug suitable for patients with osteoporosis and osteopenia. The present invention provides at least one treatment selected from the group consisting of a female hormone other than vitamin K2, bisphosphonate, ibriflavone, active vitamin D3, calcitonin, and a calcium drug for patients with osteoporosis and osteopenia having an ApoE4 genotype. It is a therapeutic drug for patients with osteoporosis and osteopenia having a selective gene using the drug. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004065696-A |
| priorityDate | 1997-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.